D-0693-2026 Class II Ongoing
FDA drug recall D-0693-2026 was initiated by Blaine Labs Inc on Apr 8, 2026 and is designated Class II. Reason for recall: CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated The recall status is ongoing. Affected quantity: 519 - 1 oz bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 8, 2026
- Initiation Date
- Apr 8, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 519 - 1 oz bottles
Product description
TRIFLUENT PHARMA TRIDERGEL Wound Care Gel, (Benzalkonium Chloride 0.1%), 1.0 fl oz, (29.6 mL) bottle with long pointy cap, Manufactured for: Trifluent Pharma, LLC. San Antonio, TX 78213. NDC 73352-520-01.
Reason for recall
CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated
Distribution pattern
Nationwide in the USA
Code information
Lot #: BL3435, Exp. 11/06/26
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0693-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026